MiMedx Agrees to Regulatory Oversight for Novel HCT/P Products

Drug Industry Daily
A A
After extensive discussions with the FDA, MiMedx has agreed to settle complaints of selling unlicensed products.

To View This Article:

Login

Subscribe To Drug Industry Daily